Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): The phase 2 SATURN study
Ophthalmology Feb 27, 2019
Heissigerova J, et al. - Researchers analyzed 58 candidates to analyze the effectiveness and safety of sarilumab (a human anti-interleukin-6 receptor antibody) to treat posterior segment noninfectious uveitis (NIU). They noticed a significant decline in the mean vitreous haze (VH) from baseline to week 16 with sarilumab vs placebo despite of assessment by the central reading center (−2.1 vs −1.7, respectively) or investigator (−2.5 vs −1.2) in the subgroup of eyes with VH grade ≥2 at baseline. They recorded a greater value of mean best-corrected visual acuity gain from baseline to week 16 with sarilumab vs placebo in the overall population (8.9 vs 3.6 letters, respectively) and in the subgroup of eyes with central subfield thickness (CST) ≥300 μm at baseline. They also found common ocular adverse events like worsening of uveitis and retinal infiltrates. Overall, they suggested subcutaneous sarilumab in the management of NIU of the posterior segment, especially in eyes with uveitic macular edema.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries